Genentech is teaming up with Bicycle Therapeutics to develop cancer immunotherapies. Bicycle uses chemical scaffolds to turn linear peptides into two pretzel-like loops. The firm says these so-called bicyclic peptides can be used as drugs alone or to deliver toxic payloads to cancer cells. Bicycle has several cancer drug programs of its own. Genentech will pay Bicycle $30 million up front—and up to $1.7 billion in milestone payments—to develop bicyclic peptides against several new targets.

    10.1021/cen-09809-buscon18-bicycle-gr1

    Bicycle's bicyclic peptides can be linked to anticancer toxins. (Credit: Bicycle/C&EN)

    Bicyclic peptidesimmunotherapyAn image of Bicycle's bicyclic peptide.


    Zugriff

    Zugriff prüfen

    Verfügbarkeit in meiner Bibliothek prüfen

    Bestellung bei Subito €


    Exportieren, teilen und zitieren



    Titel :

    Genentech strikes deal with Bicycle


    Erschienen in:

    Erscheinungsdatum :

    09.03.2020




    Medientyp :

    Aufsatz (Zeitschrift)


    Format :

    Elektronische Ressource


    Sprache :

    Unbekannt